Novel First-In-Class NCE Targeting GPR55, a Pro-Inflammatory Orphan Cannabinoid Receptor
Time: 9:30 am
day: Day Two
Details:
- Assessing GPR55 as a target for reducing neuroinflammation and neuropathic pain in preclinical studies
- Advancing a GPR55-targeting drug in preclinical development to address chemotherapy-induced peripheral neuropathy, mitigating pain without interfering with cancer treatment, crucial for maintaining patient compliance with chemotherapy regimens
- Demonstrating the significant impact of this novel compound on mitochondrial health and GPR55 signalling, offering potential breakthroughs in treating Parkinson’s disease and various cancers
